US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

0.8402

+0.04025.03%

Post-market: 0.84920.0090+1.07%18:44 EDT

Volume:162.62K

Turnover:130.10K

Market Cap:38.22M

PE:-0.39

High:0.8402

Open:0.7956

Low:0.7542

Close:0.8000

Loading ...

Overview Company News Filings

Opus Genetics- in Jan, Got Paragraph Iv Certification Notice From Winston & Strawn, Counsel to Sandoz Incorporated

THOMSON REUTERS

Opus Genetics Inc expected to post a loss of 5 cents a share - Earnings Preview

Opus Genetics gets Fast Track designation for phentolamine ophthalmic solution

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

THOMSON REUTERS

Opus Genetics Inc - Lynx-2 Phase 3 Trial Enrollment Expected to Complete in H1 2025

THOMSON REUTERS

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

There's Been No Shortage Of Growth Recently For Iron Road's (ASX:IRD) Returns On Capital

Simply Wall St.

Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

BRIEF-Opus Genetics Announces Updates On Opgx-Lca5 Clinical Program

Opus Genetics provides update on OPGx-LCA5 clinical program

Opus Genetics Announces Updates on Opgx-Lca5 Clinical Program

THOMSON REUTERS

Opus Genetics Inc: FDA Meeting Scheduled in March 2025 to Discuss Phase 3 Trial Design and Registrational Endpoints for Opgx-Lca5

THOMSON REUTERS

Opus Genetics Inc: Initial Data on Cohort Anticipated by Q3 2025

THOMSON REUTERS

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder group nominates slate of director candidates for Opus Genetics

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

THOMSON REUTERS

Mina Sooch: Restore Value Slate Beneficially Owns About 4.1% of Opus Genetics' Outstanding Shares

THOMSON REUTERS

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

BRIEF-Opus Genetics Files For Offering Of Up To $40 Mln Common Stock - SEC Filing

Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IRD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":0.8402,"timestamp":1745611200000,"preClose":0.8,"halted":0,"volume":162623,"hourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"delay":0,"floatShares":36127791,"shares":45483823,"eps":-2.153504,"marketStatus":"Market Closed","change":0.0402,"latestTime":"04-25 16:00:00 EDT","open":0.7956,"high":0.8402,"low":0.7542,"amount":130101.92891909998,"amplitude":0.1075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.153504,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.8,"latestTime":"08:57 EDT","volume":123,"amount":98.4599994,"timestamp":1745585844295},"postHourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"volumeRatio":1.143454403133233,"impliedVol":2.1502,"impliedVolPercentile":0.544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":36127791,"roa":"-46.90%","roe":"-152.46%","lyrEps":-2.153504,"volumeRatio":1.143454403133233,"shares":45483823,"dividePrice":0,"high":0.8402,"amplitude":0.1075,"preClose":0.8,"low":0.7542,"week52Low":0.65,"pbRate":"5.68","psRate":"3.48","week52High":2.18,"institutionHeld":0,"latestPrice":0.8402,"eps":-2.153504,"divideRate":0,"volume":162623,"delay":0,"ttmEps":-2.153504,"open":0.7956,"prevYearClose":1.19,"prevWeekClose":0.7599,"prevMonthClose":0.9818,"prevQuarterClose":0.9818,"fiveDayClose":0.7599,"twentyDayClose":0.9903,"sixtyDayClose":1.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517984645","title":"Opus Genetics- in Jan, Got Paragraph Iv Certification Notice From Winston & Strawn, Counsel to Sandoz Incorporated","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984645?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:55","pubTimestamp":1741125344,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN10K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2516679046","title":"Opus Genetics Inc  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679046?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:48","pubTimestamp":1741096090,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc  expected to post a loss of5cents a share - Earnings Preview Opus Genetics Inc IRD.OQ IRD.O is expected to show a rise in quarterly revenue when it reports  results on March 6 (estim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN1H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2514538830","title":"Opus Genetics gets Fast Track designation for phentolamine ophthalmic solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2514538830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514538830?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:17","pubTimestamp":1740575840,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-gets-fast-track-designation-for-phentolamine-ophthalmic-solution?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-gets-fast-track-designation-for-phentolamine-ophthalmic-solution?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00BFXG0V08.USD","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","IRD","BK4585","BK4104","BK4007","FAST","BK4567"],"gpt_icon":0},{"id":"2514832474","title":"Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832474?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA2DXNQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2514832221","title":"Opus Genetics Inc - Lynx-2 Phase 3 Trial Enrollment Expected to Complete in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832221?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA2DXNQV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2514320488","title":"Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320488","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514320488?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Enrollment completion in LYNX-2 pivotal Phase 3 trial expected in first half of 2025. Enrollment now complete in VEGA-3 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia. VEGA-3 is a randomized, double-masked, placebo-controlled, multi-center, Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% in 545 participants with presbyopia. The primary endpoint is the percentage of participants with 15-letter improvement in photopic binocular distance-corrected near visual acuity  on the eighth day following their first visit. Participants are being followed a total of 48 weeks to collect chronic safety data. Recruitment has taken place","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-fda-fast-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BYQQ9H92.USD","BK4007","IRD","IE00BFXG0V08.USD","IE00B5TLWC47.USD","LCA","FAST","BK4567","BK4588","BK4585","BK4104"],"gpt_icon":0},{"id":"2513836567","title":"There's Been No Shortage Of Growth Recently For Iron Road's (ASX:IRD) Returns On Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513836567","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513836567?lang=en_us&edition=fundamental","pubTime":"2025-02-23 08:16","pubTimestamp":1740269776,"startTime":"0","endTime":"0","summary":"Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Ideally, a business will show two trends; firstly a growing return on capital employed  and secondly, an increasing amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. Speaking of which, we noticed some great changes in Iron Road's  returns on capital, so let's have a look.For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Iron Road, this is the formula:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . Therefore, Iron Road has an ROCE of 4.1%. Ultimately, that's a low return and it under-performs the Metals and Mining industry average of 9.6%.ASX:IRD Return on Capital Employed February 23rd 2025. If you want to search for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/theres-no-shortage-growth-recently-001616461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["EBIT","BK7129","IRD","BK4007","IRD.AU"],"gpt_icon":0},{"id":"2512067891","title":"Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512067891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512067891?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:22","pubTimestamp":1739967720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 19, 2025 07:22 ET (12:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2512168306","title":"BRIEF-Opus Genetics Announces Updates On Opgx-Lca5 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512168306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512168306?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:03","pubTimestamp":1739887405,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Announces Updates On Opgx-Lca5 Clinical ProgramFeb 18 (Reuters) - Opus Genetics Inc IRD.O:OPUS GENETICS ANNOUNCES UPDATES ON OPGX-LCA5 CLINICAL PROGRAMOPUS GENETICS INC: FDA MEETIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA5H2YJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2512315459","title":"Opus Genetics provides update on OPGx-LCA5 clinical program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512315459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512315459?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:43","pubTimestamp":1739882593,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its investig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-provides-update-on-opgx-lca5-clinical-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-provides-update-on-opgx-lca5-clinical-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2512927151","title":"Opus Genetics Announces Updates on Opgx-Lca5 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512927151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512927151?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA5H2YJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2512519091","title":"Opus Genetics Inc: FDA Meeting Scheduled in March 2025 to Discuss Phase 3 Trial Design and Registrational Endpoints for Opgx-Lca5","url":"https://stock-news.laohu8.com/highlight/detail?id=2512519091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512519091?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA5H2YJ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2512151922","title":"Opus Genetics Inc: Initial Data on Cohort Anticipated by Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151922?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA5H2YJ6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2512151008","title":"Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151008?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881800,"startTime":"0","endTime":"0","summary":"First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5. This clinical trial was designed to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-LCA5 in patients with inherited retinal degeneration due to biallelic mutations in theLCA5gene. It is an open-label, Phase 1/2 trial evaluating OPGx-LCA5. Efficacy endpoints include measurement of functional vision using: 1) the Multi-Luminance orientation and Mobility Test ; 2) Full-Field Stimulus Testing , which measures the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-updates-opgx-123000259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCA","KOL","IRD","BK4007"],"gpt_icon":0},{"id":"2509741535","title":"Shareholder group nominates slate of director candidates for Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2509741535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509741535?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:20","pubTimestamp":1738938010,"startTime":"0","endTime":"0","summary":"Mina Sooch, founder of Ocuphire Pharma, now known as Opus Genetics (IRD), announced that she has nominated a slate of seven candidates for election...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shareholder-group-nominates-slate-of-director-candidates-for-opus-genetics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shareholder-group-nominates-slate-of-director-candidates-for-opus-genetics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2509749017","title":"Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509749017","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509749017?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:15","pubTimestamp":1738937700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA7RKNLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2509049749","title":"Mina Sooch: Restore Value Slate Beneficially Owns About 4.1% of Opus Genetics' Outstanding Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509049749","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509049749?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:15","pubTimestamp":1738937700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA7RKNLF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2509740857","title":"Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509740857","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509740857?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:15","pubTimestamp":1738937700,"startTime":"0","endTime":"0","summary":"Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months. New Leadership is Urgently Needed to Restore Accountability in the Boardroom. Restore Value Slate Brings Deep Industry Expertise, Operational Discipline, and Strong Shareholder Alignment. If elected, the Nominees will bring the leadership, accountability, and transparency necessary to restore long-term shareholder value without further dilution. The Restore Value Slate is committed to addressing the critical governance and operational failures that have persisted under the current Board. The Company has scheduled the Annual Meeting significantly earlier than in previous years, setting the date for April 30, 2025. This accelerated timeline shortens the typical window for shareholder engagement ahead of this pivotal election. Stockholders are encouraged to review the Restore Value Slate’s materials as they become available and reach out for further information thro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholder-group-led-founder-mina-141500692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4500","BK4007","CPA","BK4008","IRD"],"gpt_icon":0},{"id":"2503574815","title":"BRIEF-Opus Genetics Files For Offering Of Up To $40 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2503574815","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503574815?lang=en_us&edition=fundamental","pubTime":"2025-01-14 07:29","pubTimestamp":1736810989,"startTime":"0","endTime":"0","summary":"Jan 13 (Reuters) - SEC Filing:   * OPUS GENETICS INC FILES FOR OFFERING OF UP TO $40 MILLION COMMON STOCK - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","UP","BK4008"],"gpt_icon":0},{"id":"2492120528","title":"Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120528?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613551,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, SPA,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPA","IRD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2024-05-10","symbol":"IRD","fiscalQuarterEnding":"2024/03","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-03-08","symbol":"IRD","fiscalQuarterEnding":"2023/12","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1709874000000,"reportTimeType":"pre","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-04-25","current":-0.632466,"percent":0.92562,"low":-2.964142,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"high":-0.560128,"avg":-1.33286,"sd":0.500679,"marketCap":36387058},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058}],"updateTime":1745740290246}}}